GeneTx and Ultragenyx Announce Investigational New Drug (IND) Application Active for GTX-102 in Patients with Angelman Syndrome
Go back to GeneTx and Ultragenyx Announce Investigational New Drug (IND) Application Active for GTX-102 in Patients with Angelman Syndrome| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 29.11 +0.35 (1.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.76 | 52 Week High | $117.12 | |||
| Open | $29.02 | 52 Week Low | $46.52 | |||
| Day High | $30.14 | P/E | N/A | |||
| Day Low | $29.01 | EPS | $-1.97 | |||
| Volume | 1,727,751 | |||||
